問卷

TPIDB > Search Result

Search Result

篩選

List

140Cases

2022-05-10 - 2027-07-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-11-30 - 2028-11-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-03-01 - 2023-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2024-11-29

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-07-01 - 2028-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-15 - 2032-12-01

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2032-03-02

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-08-01 - 2026-12-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2022-04-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-12-01 - 2022-12-31

Phase I/II

A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors
  • Condition/Disease

    Advanced Refractory Solid Tumors

  • Test Drug

    CS1001 Regorafenib

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites